Taysha Gene Therapies (TSHA) Income towards Parent Company (2020 - 2026)

Taysha Gene Therapies has reported Income towards Parent Company for 7 years, with the latest figure at -$98.1 million in Q1 2026.

• Quarterly Income towards Parent Company fell 243.13% year-over-year to -$98.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$236.7 million (down 76.18% YoY) and the FY2025 annual result came in at -$183.0 million, up 7.9% from the prior year.
• Income towards Parent Company fell to -$98.1 million in Q1 2026 per TSHA's latest filing, from -$25.4 million in the prior quarter.
• Over five years, Income towards Parent Company peaked at -$15.7 million in Q4 2023 and troughed at -$98.1 million in Q1 2026.
• A 5-year average of -$41.2 million and a median of -$34.1 million in 2022 frame the typical range for Income towards Parent Company.
• The sharpest annual moves came in 2023 and 2026: Income towards Parent Company surged 72.04% in 2023, then slumped 243.13% in 2026.
• Over 5 years, Income towards Parent Company stood at -$56.0 million in 2022, then soared by 72.04% to -$15.7 million in 2023, then sank by 49.66% to -$23.4 million in 2024, then dropped by 8.57% to -$25.4 million in 2025, then sank by 285.64% to -$98.1 million in 2026.
• According to Business Quant data, Income towards Parent Company over the past three periods registered -$98.1 million, -$25.4 million, and -$62.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.